# reload+after+2024-01-22 15:43:10.984856
address1§100 Cardinal Way
city§Redwood City
state§CA
zip§94063
country§United States
phone§650 656 9323
fax§650 649 1995
website§https://adverum.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
fullTimeEmployees§123
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Laurent  Fischer', 'age': 59, 'title': 'President, CEO & Director', 'yearBorn': 1964, 'fiscalYear': 2022, 'totalPay': 977228, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Linda M. Rubinstein M.A.', 'age': 56, 'title': 'CFO, Principal Financial Officer & Principal Accounting Officer', 'yearBorn': 1967, 'fiscalYear': 2022, 'totalPay': 111888, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Kishor Peter Soparkar J.D.', 'age': 52, 'title': 'Chief Operating Officer', 'yearBorn': 1971, 'fiscalYear': 2022, 'totalPay': 656959, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. John W. Rakow J.D.', 'age': 66, 'title': 'Senior VP & General Counsel', 'yearBorn': 1957, 'fiscalYear': 2022, 'totalPay': 954237, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Setareh  Seyedkazemi Pharm.D.', 'age': 49, 'title': 'Chief Development Officer', 'yearBorn': 1974, 'fiscalYear': 2022, 'totalPay': 834572, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. R. Andrew Ramelmeier Ph.D.', 'age': 61, 'title': 'Chief Technology Officer', 'yearBorn': 1962, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Brigit  Riley Ph.D.', 'age': 45, 'title': 'Chief Scientific Officer', 'yearBorn': 1978, 'fiscalYear': 2022, 'totalPay': 816075, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Dena  House', 'title': 'Senior Vice President of Human Resources, Organizational Development & Learning', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Carla  Fiankan', 'title': 'Senior Vice President of Regulatory Affairs', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Michael  Steel', 'title': 'Senior Vice President of Quality', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§6
boardRisk§5
compensationRisk§9
shareHolderRightsRisk§8
overallRisk§7
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§0.666
priceToSalesTrailing12Months§23.432652
currency§USD
dateShortInterest§1702598400
forwardEps§-0.89
exchange§NCM
quoteType§EQUITY
shortName§Adverum Biotechnologies, Inc.
longName§Adverum Biotechnologies, Inc.
firstTradeDateEpochUtc§1406813400
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§225fcb08-92be-3343-b3b8-e211673ed161
gmtOffSetMilliseconds§-18000000
targetHighPrice§6.0
targetLowPrice§2.0
targetMeanPrice§3.8
targetMedianPrice§4.0
recommendationMean§2.0
recommendationKey§buy
numberOfAnalystOpinions§5
quickRatio§4.057
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
